This document provides methods and materials for generating CD8.sup.+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide. For example, methods and materials for using a polypeptide consisting of an SLAFLPESFD amino acid sequence in vivo or in vitro to generate CD8.sup.+ T cells having the ability to recognize and lyse cancer cells expressing a HER2/neu polypeptide are provided.

Disclosed are hypoallergenic variants of Phl p 5, the major allergen from Phleum pratense, and the uses thereof in the treatment of allergic diseases.

Disclosed are hypoallergenic variants of Phl p 5, the major allergen from Phleum pratense, and the uses thereof in the treatment of allergic diseases.

The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introduced amount of imiquimod with the viscous encapsulating material.

A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introduced amount of imiquimod with the viscous encapsulating material.

The invention concerns the selection and characterization of synthetic peptides, which have affinity for receptors present in cells of the immune system, more particularly peptides with affinity for the TGF-β receptor and peptides with affinity for the IL-10 receptor, as well as pharmaceutical compositions and the use of such combined peptides to prepare drugs or immunogenic compositions. Said synthetic peptides can bind to cell receptors and promote an important regulatory profile for the treatment and/or prophylaxis of diseases, more particularly chronic or acute inflammatory and/or allergic diseases.

The invention concerns the selection and characterization of synthetic peptides, which have affinity for receptors present in cells of the immune system, more particularly peptides with affinity for the TGF-β receptor and peptides with affinity for the IL-10 receptor, as well as pharmaceutical compositions and the use of such combined peptides to prepare drugs or immunogenic compositions. Said synthetic peptides can bind to cell receptors and promote an important regulatory profile for the treatment and/or prophylaxis of diseases, more particularly chronic or acute inflammatory and/or allergic diseases.

The present disclosure provides a novel method for modulating mucosal immune response, comprising administering an antigen to a mucosal site of a subject in need thereof, and administering an immunomodulator to a different anatomical mucosal site of said subject. The antigen may be administered to sublingual mucosa and the immunomodulator may be administered to intranasal mucosa. An immune response involving production of IgG and IgA against the antigen may be elicited.